Oral Tranexamic Acid for the Treatment of Melasma: A Case Series and Novel Dosing Regimen
Document Type
Article
Publication Title
Journal of Drugs in Dermatology
Abstract
Melasma is a common disorder affecting millions of people around the world. It is a condition that can disrupt one’s self-esteem and overall quality of life. Melasma is characterized by hyperpigmented macules and patches on the face. The pathophysiology of melasma is widely unknown, although multiple triggers have been identified. Among the triggers, sun exposure is considered to be the most important factor. A variety of topical treatments exist for melasma, however most of these options often lead to subpar results. Due to this, novel treatments such as oral tranexamic acid (TXA) have emerged. Our case series demonstrates the effectiveness and safety profile of utilizing oral TXA to treat recalcitrant melasma and highlights a possible dosing regimen that can be used for the novel therapy.
DOI
10.36849/JDD.6663
Publication Date
4-1-2022
ISSN
1545-9616
Recommended Citation
Foss M, Nethers K, Bhukhan A, Nathoo R. Oral Tranexamic Acid for the Treatment of Melasma: A Case Series and Novel Dosing Regimen. Journal of Drugs in Dermatology. 2022; 21(4). doi: 10.36849/JDD.6663.
